FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Alan Breier

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Melissa Spann; Stacy Lindborg; John Seaman; Robert Baker; Eduardo Dunayevich; Alan Breier
Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach.
Keith A Hawkins; Richard S E Keefe; Bruce K Christensen; Jean Addington; Scott W Woods; Jennifer Callahan; Robert B Zipursky; Diana O Perkins; Mauricio Tohen; Alan Breier; Thomas H McGlashan
Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study.
David H Adams; Sandra Close; Mark Farmen; Anncatherine M Downing; Alan Breier; John P Houston
Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Alan Breier (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Melissa Spann; Stacy Lindborg; John Seaman; Robert Baker; Eduardo Dunayevich; Alan Breier
Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach.
Journal of psychiatric research 2009;43(5):561-7.
2008: Keith A Hawkins; Richard S E Keefe; Bruce K Christensen; Jean Addington; Scott W Woods; Jennifer Callahan; Robert B Zipursky; Diana O Perkins; Mauricio Tohen; Alan Breier; Thomas H McGlashan
Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study.
Schizophrenia research 2008;105(1-3):1-9.
2008: David H Adams; Sandra Close; Mark Farmen; Anncatherine M Downing; Alan Breier; John P Houston
Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder.
Human psychopharmacology 2008;23(4):267-74.
2007: Ralph E Hoffman; Scott W Woods; Keith A Hawkins; Brian Pittman; Mauricio Tohen; Adrian Preda; Alan Breier; Jill Glist; Jean Addington; Diana O Perkins; Thomas H McGlashan
Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population.
The British journal of psychiatry : the journal of mental science 2007;191():355-6.
2007: John P Houston; David H Adams; Sandra C Kirkwood; Mark Farmen; AnnCatherine M Downing; Alan Breier
Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophrenia.
Journal of clinical psychopharmacology 2007;27(5):520-3.
2007: Alan Breier; Larry Alphs; Brendon Binneman
Wayne Fenton's impact on industry.
Schizophrenia bulletin 2007;33(5):1154-5.
2006: Christopher Carlson; Kenneth Hornbuckle; Frank DeLisle; Ludmila Kryzhanovskaya; Alan Breier; Patrizia Cavazzoni
Diabetes mellitus and antipsychotic treatment in the United Kingdom.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2006;16(5):366-75.
2006: Thomas H McGlashan; Robert B Zipursky; Diana O Perkins; Jean Addington; Tandy Miller; Scott W Woods; Keith A Hawkins; Ralph E Hoffman; Adrian Preda; Irvin Epstein; Donald Addington; Stacy R Lindborg; Quynh Trzaskoma; Mauricio Tohen; Alan Breier
Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.
The American journal of psychiatry 2006;163(5):790-9.
2006: Richard S E Keefe; Carrie A Young; Stephanie L Rock; Scot E Purdon; James M Gold; Alan Breier
One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.
Schizophrenia research 2006;81(1):1-15.
2005: Alan Breier; Paul H Berg; Jogin H Thakore; Dieter Naber; Wagner F Gattaz; Patrizia Cavazzoni; Daniel J Walker; Suraja M Roychowdhury; John M Kane
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
The American journal of psychiatry 2005;162(10):1879-87.
2005: Alan Breier
Developing drugs for cognitive impairment in schizophrenia.
Schizophrenia bulletin 2005;31(4):816-22.
2005: Kelvin Lin-Yu Chou; Susan Messing; David Oakes; Peter Feldman; Alan Breier; Joseph H Friedman
Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments.
Clinical neuropharmacology 2005;28(5):215-9.
2005: Walter Deberdt; Maurice W Dysken; Stephen A Rappaport; Peter Feldman; Carrie A Young; Donald P Hay; Deborah L Lehman; Martin Dossenbach; Elisabeth K Degenhardt; Alan Breier
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2005;13(8):722-30.
2005: Maurício Silva de Lima; Jair de Jesus Mari; Alan Breier; Anna Maria Costa; Eduardo Pondé de Sena; Matthew Hotopf
Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics.
The Journal of clinical psychiatry 2005;66(7):831-8.
2005: John H Krystal; Walid Abi-Saab; Edward Perry; D Cyril D'Souza; Nianjun Liu; Ralitza Gueorguieva; Lisa McDougall; Tracy Hunsberger; Aysenil Belger; Louise Levine; Alan Breier
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.
Psychopharmacology 2005;179(1):303-9.
2005: Josep Maria Haro; Eric T Edgell; Diego Novick; J Alonso; Liam Kennedy; Peter B Jones; Mark Ratcliffe; Alan Breier
Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study.
Acta psychiatrica Scandinavica 2005;111(3):220-31.
2005: Walter Deberdt; Andrew Winokur; Patrizia Cavazzoni; Quynh N Trzaskoma; Christopher D Carlson; Frank P Bymaster; Karen Wiener; Michel Floris; Alan Breier
Amantadine for weight gain associated with olanzapine treatment.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2005;15(1):13-21.
2004: Igor Elman; David Rott; Alan I Green; Daniel D Langleben; Scott E Lukas; David S Goldstein; Alan Breier
Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia.
Psychopharmacology 2004;176(3-4):369-75.
2004: Madhav A Namjoshi; Richard Risser; Lizheng Shi; Mauricio Tohen; Alan Breier
Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid.
Journal of affective disorders 2004;81(3):223-9.
2004: Vivian Mitropoulou; Marianne Goodman; Serge Sevy; Igor Elman; Antonia S New; Elisabeth G Iskander; Jeremy Silverman; Alan Breier; Larry J Siever
Effects of acute metabolic stress on the dopaminergic and pituitary-adrenal axis activity in patients with schizotypal personality disorder.
Schizophrenia research 2004;70(1):27-31.
2004: Patrizia Cavazzoni; Nitai Mukhopadhyay; Christopher Carlson; Alan Breier; John B Buse
Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications.
The British journal of psychiatry. Supplement 2004;47():S94-101.
2004: Keith A Hawkins; Jean Addington; Richard S E Keefe; B Christensen; Diana O Perkins; R Zipurksy; Scott W Woods; Tandy J Miller; Eva Marquez; Alan Breier; Thomas H McGlashan
Neuropsychological status of subjects at high risk for a first episode of psychosis.
Schizophrenia research 2004;67(2-3):115-22.
2004: Peter Paul De Deyn; Manuel Martín Carrasco; Walter Deberdt; Claude Jeandel; Donald P Hay; Peter Feldman; Carrie A Young; Deborah L Lehman; Alan Breier
Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.
International journal of geriatric psychiatry 2004;19(2):115-26.
2004: Zhongyun Zhao; Madhav Namjoshi; Beth L Barber; Danielle L Loosbrock; Sandra L Tunis; Baojin Zhu; Alan Breier
Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database.
CNS drugs 2004;18(3):157-64.
2004: Peter Feldman; Linda K Hay; Walter Deberdt; John S Kennedy; David S Hutchins; Donald P Hay; Thomas A Hardy; Vicki Poole Hoffmann; Kenneth Hornbuckle; Alan Breier
Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States.
Journal of the American Medical Directors Association 2004;5(1):38-46.
2004: István Bitter; Martin Dossenbach; Shlomo Brook; Peter Feldman; Stephen Metcalfe; Carlo A Gagiano; János Füredi; György Bartko; Zoltan Janka; Csaba M Banki; Gabor Kovacs; Alan Breier
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.
Progress in neuro-psychopharmacology & biological psychiatry 2004;28(1):173-80.
2003: Padraig Wright; Stacy R Lindborg; Martin Birkett; Karena Meehan; Barry Jones; Karla Alaka; Iris Ferchland-Howe; Anne Pickard; Cindy C Taylor; John Roth; John Battaglia; István Bitter; Guy Chouinard; Philip L P Morris; Alan Breier
Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.
Canadian journal of psychiatry. Revue canadienne de psychiatrie 2003;48(11):716-21.
2003: Margaret Sowell; Nitai Mukhopadhyay; Patrizia Cavazzoni; Christopher Carlson; Sunder Mudaliar; Sithiphol Chinnapongse; Amy Ray; Trent Davis; Alan Breier; Robert R Henry; Jamie Dananberg
Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp.
The Journal of clinical endocrinology and metabolism 2003;88(12):5875-80.
2003: Mauricio Tohen; Joseph F Goldberg; Ana Maria Gonzalez-Pinto Arrillaga; Jean M Azorin; Eduard Vieta; Marie-Christine Hardy-Bayle; William B Lawson; Robin A Emsley; Fan Zhang; Robert W Baker; Richard Risser; Madhav A Namjoshi; Angela R Evans; Alan Breier
A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania.
Archives of general psychiatry 2003;60(12):1218-26.
2003: John S Kennedy; D Jeste; Christopher J Kaiser; S Golshan; Gerald A Maguire; Gary D Tollefson; Todd M Sanger; Frank P Bymaster; Bruce J Kinon; Martin Dossenbach; Julie A Gilmore; Alan Breier
Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
International journal of geriatric psychiatry 2003;18(11):1013-20.
2003: Mauricio Tohen; Eduard Vieta; Joseph Calabrese; Terence A Ketter; Gary Sachs; Charles L Bowden; Philip B Mitchell; Franca Centorrino; Richard Risser; Robert W Baker; Angela R Evans; Karin Beymer; Sanjay Dube; Gary D Tollefson; Alan Breier
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
Archives of general psychiatry 2003;60(11):1079-88.
2003: Thomas Hardy; Alan Breier
Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes: response to Lean and Pajonk.
Diabetes care 2003;26(11):3200-1.
2003: Peter Feldman; Christopher J Kaiser; John S Kennedy; Virginia K Sutton; Pierre V Tran; Gary D Tollefson; Fan Zhang; Alan Breier
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.
The Journal of clinical psychiatry 2003;64(9):998-1004.
2003: Igor Elman; Scott E Lukas; Susan E Shoaf; David Rott; Caleb Adler; Alan Breier
Effects of acute metabolic stress on the peripheral vasopressinergic system in schizophrenia.
Journal of psychopharmacology (Oxford, England) 2003;17(3):317-23.
2003: Scott W Woods; Alan Breier; Robert B Zipursky; Diana O Perkins; Jean Addington; Tandy J Miller; Keith A Hawkins; Eva Marquez; Stacy R Lindborg; Mauricio Tohen; Thomas H McGlashan
Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome.
Biological psychiatry 2003;54(4):453-64.
2003: Celso Arango; Alan Breier; Robert P McMahon; William T Carpenter; Robert W Buchanan
The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes.
The American journal of psychiatry 2003;160(8):1421-7.
2003: Padraig Wright; Karena Meehan; Martin Birkett; Stacy R Lindborg; Cindy C Taylor; Philip Morris; Alan Breier
A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy.
Clinical therapeutics 2003;25(5):1420-8.
2003: Tandy J Miller; Robert B Zipursky; Diana O Perkins; Jean Addington; Scott W Woods; Keith A Hawkins; Rosalind Hoffman; Adrian Preda; I Epstein; D Addington; Stacy R Lindborg; Eva Marquez; Mauricio Tohen; Alan Breier; Thomas H McGlashan
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.
Schizophrenia research 2003;61(1):19-30.
2003: Thomas H McGlashan; Robert B Zipursky; Diana O Perkins; Jean Addington; Tandy J Miller; Scott W Woods; Keith A Hawkins; Rosalind Hoffman; Stacy R Lindborg; Mauricio Tohen; Alan Breier
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design.
Schizophrenia research 2003;61(1):7-18.
2003: Patrizia Cavazzoni; Yoko Tanaka; Suraja M Roychowdhury; Alan Breier; David Allison
Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2003;13(2):81-5.
2003: John B Buse; Patrizia Cavazzoni; Kenneth Hornbuckle; David Hutchins; Alan Breier; Lois Jovanovic
A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States.
Journal of clinical epidemiology 2003;56(2):164-70.
2003: Todd M Sanger; Mauricio Tohen; Eduard Vieta; David L Dunner; Charles L Bowden; Joseph Calabrese; Peter Feldman; Thomas G Jacobs; Alan Breier
Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling.
Journal of affective disorders 2003;73(1-2):155-61.
2002: Alan Breier; Virginia K Sutton; Peter Feldman; Deborah L Kadam; Iris Ferchland; Padraig Wright; Joseph H Friedman
Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease.
Biological psychiatry 2002;52(5):438-45.
2002: Lizheng Shi; Madhav A Namjoshi; Fan Zhang; Gian Gandhi; Eric T Edgell; Mauricio Tohen; Alan Breier; Josep Maria Haro
Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status.
International clinical psychopharmacology 2002;17(5):227-37.
2002: Igor Elman; David S Goldstein; Alan I Green; Graeme Eisenhofer; Carol J Folio; Courtney S Holmes; DAVID PICKAR; Alan Breier
Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia: a comparison with clozapine and placebo.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2002;27(2):293-300.
2002: Margaret O Sowell; Nitai Mukhopadhyay; Patrizia Cavazzoni; Sudha Shankar; Helmut O Steinberg; Alan Breier; Charles Beasley; Jamie Dananberg
Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.
The Journal of clinical endocrinology and metabolism 2002;87(6):2918-23.
2002: Mauricio Tohen; Robert W Baker; Lori L Altshuler; Carlos A Zarate; Trisha Suppes; Terence A Ketter; Denái R Milton; Richard Risser; Julie A Gilmore; Alan Breier; Gary A Tollefson
Olanzapine versus divalproex in the treatment of acute mania.
The American journal of psychiatry 2002;159(6):1011-7.
2002: Madhav A Namjoshi; Gopalan Rajamannar; Thomas Jacobs; Todd M Sanger; Richard Risser; Mauricio Tohen; Alan Breier; Paul E Keck
Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial.
Journal of affective disorders 2002;69(1-3):109-18.
2002: Alan Breier; Karena Meehan; Martin Birkett; Stacy David; Iris Ferchland; Virginia K Sutton; Cindy C Taylor; Rebecca Palmer; Martin Dossenbach; Geri Kiesler; Shlomo Brook; Padraig Wright
A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
Archives of general psychiatry 2002;59(5):441-8.
2002: Karena Meehan; Huei Wang; Stacy R David; Jennifer R Nisivoccia; Barry Jones; Charles Beasley; Peter Feldman; Jacobo E Mintzer; Louise M Beckett; Alan Breier
Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2002;26(4):494-504.
2002: Caleb M Adler; Anil Malhotra; Igor Elman; DAVID PICKAR; Alan Breier
Amphetamine-induced dopamine release and post-synaptic specific binding in patients with mild tardive dyskinesia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2002;26(3):295-300.
2002: Mauricio Tohen; K N Roy Chengappa; Trisha Suppes; Carlos A Zarate; Joseph Calabrese; Charles L Bowden; Gary S Sachs; David J Kupfer; Robert W Baker; Richard Risser; Elisabeth L Keeter; Peter Feldman; Gary D Tollefson; Alan Breier
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.
Archives of general psychiatry 2002;59(1):62-9.
2001: Mauricio Tohen; Fan Zhang; Paul E Keck; Peter Feldman; Richard Risser; Pierre V Tran; Alan Breier
Olanzapine versus haloperidol in schizoaffective disorder, bipolar type.
Journal of affective disorders 2001;67(1-3):133-40.
2001: Jacobo E Mintzer; Warachal Eileen Faison; J S Street; V K Sutton; Alan Breier
Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis.
International journal of geriatric psychiatry 2001;16 Suppl 1():S71-7.
2001: JS Street; WS Clark; Deborah L Kadam; S J Mitan; B E Juliar; Peter Feldman; Alan Breier
Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia.
International journal of geriatric psychiatry 2001;16 Suppl 1():S62-70.
2001: John S Kennedy; Frank P Bymaster; Leslie M Schuh; David O Calligaro; George Nomikos; Christian Felder; M Bernauer; Bruce J Kinon; Robert W Baker; D Hay; H J Roth; Martin Dossenbach; C Kaiser; Charles Beasley; John H Holcombe; M B Effron; Alan Breier
A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data.
International journal of geriatric psychiatry 2001;16 Suppl 1():S33-61.
2001: John S Kennedy; A Zagar; Frank P Bymaster; George Nomikos; Paula T Trzepacz; Julie A Gilmore; Matthew D Rotelli; Alan Breier; Gary D Tollefson
The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease.
International journal of geriatric psychiatry 2001;16 Suppl 1():S24-32.
2001: Karena Meehan; Fan Zhang; S David; Mauricio Tohen; P Janicak; J Small; M Koch; R Rizk; D Walker; P Tran; Alan Breier
A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania.
Journal of clinical psychopharmacology 2001;21(4):389-97.
2001: Padraig Wright; Martin Birkett; S R David; Karena Meehan; Iris Ferchland; Karla Alaka; J C Saunders; J Krueger; P Bradley; L San; M Bernardo; M Reinstein; Alan Breier
Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.
The American journal of psychiatry 2001;158(7):1149-51.
2001: Igor Elman; David S Goldstein; Caleb M Adler; S E Shoaf; Alan Breier
Inverse relationship between plasma epinephrine and testosterone levels during acute glucoprivation in healthy men.
Life sciences 2001;68(16):1889-98.
2001: WS Clark; JS Street; Peter Feldman; Alan Breier
The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
The Journal of clinical psychiatry 2001;62(1):34-40.
2001: Alan Breier
Introduction: a new era in the pharmacotherapy of psychotic disorders.
The Journal of clinical psychiatry 2001;62 Suppl 2():3-5.
2000: Eric T Edgell; S W Andersen; B M Johnstone; B Dulisse; D Revicki; Alan Breier
Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.
PharmacoEconomics 2000;18(6):567-79.
2000: JS Street; WS Clark; K S Gannon; Jeffrey L Cummings; Frank P Bymaster; Roy Tamura; S J Mitan; Deborah L Kadam; Todd M Sanger; Peter Feldman; Gary D Tollefson; Alan Breier
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.
Archives of general psychiatry 2000;57(10):968-76.
2000: Alan Breier; Robert W Buchanan; D Irish; William T Carpenter
Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. 1993.
Psychiatric services (Washington, D.C.) 2000;51(10):1249-53.
2000: William T Carpenter; Alan Breier; Robert W Buchanan; Brian Kirkpatrick; Paul D Shepard; Elaine Weiner
Mazindol treatment of negative symptoms.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2000;23(4):365-74.
2000: Stacy R David; Cindy C Taylor; Bruce J Kinon; Alan Breier
The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
Clinical therapeutics 2000;22(9):1085-96.
2000: Susan H Hamilton; Eric T Edgell; Dennis A Revicki; Alan Breier
Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample.
International clinical psychopharmacology 2000;15(5):245-55.
2000: Mauricio Tohen; Thomas G Jacobs; SL Grundy; S L McElroy; M C Banov; P G Janicak; Todd M Sanger; Richard Risser; Fan Zhang; V Toma; J Francis; Gary D Tollefson; Alan Breier
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.
Archives of general psychiatry 2000;57(9):841-9.
2000: Juan-Carlos Gómez; José Antonio Sacristán; J Hernández; Alan Breier; P Ruiz Carrasco; C Antón Saiz; E Fontova Carbonell
The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.
The Journal of clinical psychiatry 2000;61(5):335-43.
2000: Caleb M Adler; Igor Elman; NI Weisenfeld; LP Kestler; DAVID PICKAR; Alan Breier
Effects of acute metabolic stress on striatal dopamine release in healthy volunteers.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2000;22(5):545-50.
2000: H Watabe; Christopher J Endres; Alan Breier; B Schmall; William Eckelman; Richard E Carson
Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2000;41(3):522-30.
2000: Scot E Purdon; B D Jones; Emmanuel Stip; Alain Labelle; Donald Addington; Stacy R David; Alan Breier; Gary D Tollefson
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
Archives of general psychiatry 2000;57(3):249-58.
2000: Alessandro Bertolino; Alan Breier; Joseph Callicott; Caleb Adler; Venkata S Mattay; M Shapiro; Joseph A Frank; DAVID PICKAR; Daniel R Weinberger
The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2000;22(2):125-32.
2000: LP Kestler; Anil Malhotra; C Finch; Caleb Adler; Alan Breier
The relation between dopamine D2 receptor density and personality: preliminary evidence from the NEO personality inventory-revised.
Neuropsychiatry, neuropsychology, and behavioral neurology 2000;13(1):48-52.
1999: Caleb M Adler; Anil Malhotra; Igor Elman; Terry Goldberg; M Egan; DAVID PICKAR; Alan Breier
Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia.
The American journal of psychiatry 1999;156(10):1646-9.
1999: Alan Breier; P H Berg
The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome.
Biological psychiatry 1999;46(3):361-4.
1999: Mary Kosmidis; Alan Breier; Bryan D Fantie
Avoidance learning in schizophrenia: a dissociation between the effects of aversive and non-aversive stimuli.
Schizophrenia research 1999;38(1):51-9.
1999: N L Bryant; Robert W Buchanan; K Vladar; Alan Breier; MI Rothman
Gender differences in temporal lobe structures of patients with schizophrenia: a volumetric MRI study.
The American journal of psychiatry 1999;156(4):603-9.
1999: Alan Breier; TP Su; Anil Malhotra; Igor Elman; Caleb M Adler; NI Weisenfeld; DAVID PICKAR
Effects of atypical antipsychotic drug treatment on amphetamine-induced striatal dopamine release in patients with psychotic disorders.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1999;20(4):340-5.
1999: William T Carpenter; Robert W Buchanan; Brian Kirkpatrick; H D Lann; Alan Breier; Ann Summerfelt
Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks.
The American journal of psychiatry 1999;156(3):412-8.
1999: Alan Breier; Susan H Hamilton
Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.
Biological psychiatry 1999;45(4):403-11.
1999: William T Carpenter; Robert W Buchanan; Brian Kirkpatrick; Alan Breier
Diazepam treatment of early signs of exacerbation in schizophrenia.
The American journal of psychiatry 1999;156(2):299-303.
1999: Alan Breier; Anil Malhotra; TP Su; DA Pinals; Igor Elman; Caleb M Adler; R T Lafargue; A Clifton; DAVID PICKAR
Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.
The American journal of psychiatry 1999;156(2):294-8.
1999: Igor Elman; Louis Sokoloff; Caleb M Adler; NI Weisenfeld; Alan Breier
The effects of pharmacological doses of 2-deoxyglucose on cerebral blood flow in healthy volunteers.
Brain research 1999;815(2):243-9.
1999: Alan Breier
Cognitive deficit in schizophrenia and its neurochemical basis.
The British journal of psychiatry. Supplement 1999;(37):16-8.
1999: Igor Elman; David S Goldstein; Graeme Eisenhofer; J Folio; Anil Malhotra; Caleb M Adler; DAVID PICKAR; Alan Breier
Mechanism of peripheral noradrenergic stimulation by clozapine.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1999;20(1):29-34.
1998: Anil Malhotra; Alan Breier; David Goldman; L Picken; DAVID PICKAR
The apolipoprotein E epsilon 4 allele is associated with blunting of ketamine-induced psychosis in schizophrenia. A preliminary report.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1998;19(5):445-8.
1998: Alan Breier; LP Kestler; Caleb Adler; Igor Elman; N Wiesenfeld; Anil Malhotra; DAVID PICKAR
Dopamine D2 receptor density and personal detachment in healthy subjects.
The American journal of psychiatry 1998;155(10):1440-2.
1998: Anil Malhotra; David Goldman; Chiarra Mazzanti; A Clifton; Alan Breier; DAVID PICKAR
A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics.
Molecular psychiatry 1998;3(4):328-32.
1998: Igor Elman; Caleb M Adler; Anil Malhotra; C Bir; DAVID PICKAR; Alan Breier
Effect of acute metabolic stress on pituitary-adrenal axis activation in patients with schizophrenia.
The American journal of psychiatry 1998;155(7):979-81.
1998: Robert W Buchanan; Alan Breier; Brian Kirkpatrick; M Patricia Ball; William T Carpenter
Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome.
The American journal of psychiatry 1998;155(6):751-60.
1998: Caleb M Adler; Terry Goldberg; Anil Malhotra; DAVID PICKAR; Alan Breier
Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers.
Biological psychiatry 1998;43(11):811-6.
1998: Alan Breier; Caleb M Adler; NI Weisenfeld; TP Su; Igor Elman; L Picken; Anil Malhotra; DAVID PICKAR
Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach.
Synapse (New York, N.Y.) 1998;29(2):142-7.
1998: Alessandro Bertolino; Joseph Callicott; I Elman; Venkata S Mattay; Gioacchino Tedeschi; Joseph A Frank; Alan Breier; Daniel R Weinberger
Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study.
Biological psychiatry 1998;43(9):641-8.
1998: DA Pinals; Anil Malhotra; Alan Breier; DAVID PICKAR
Informed consent in schizophrenia research.
Psychiatric services (Washington, D.C.) 1998;49(2):244.
1998: Anil Malhotra; David Goldman; Robert W Buchanan; W Rooney; A Clifton; Mary Kosmidis; Alan Breier; DAVID PICKAR
The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response.
Molecular psychiatry 1998;3(1):72-5.
1998: Alan Breier; Igor Elman; David S Goldstein
Norepinephrine and schizophrenia: a new hypothesis for antipsychotic drug action.
Advances in pharmacology (San Diego, Calif.) 1998;42():785-8.
1997: Anil Malhotra; Caleb M Adler; S D Kennison; Igor Elman; DAVID PICKAR; Alan Breier
Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine.
Biological psychiatry 1997;42(8):664-8.
1997: Brian Kirkpatrick; D Litman; J W Kim; K Vladar; Alan Breier; Robert W Buchanan
Failure of fusion of the septum pellucidum and the heterogeneity of schizophrenia.
The Journal of nervous and mental disease 1997;185(10):639-41.
1997: T P Su; Anil Malhotra; K Hadd; Alan Breier; DAVID PICKAR
D2 dopamine receptor occupancy: a crossover comparison of risperidone with clozapine therapy in schizophrenic patients.
Archives of general psychiatry 1997;54(10):972-3.
1997: DAVID PICKAR; Anil Malhotra; W Rooney; Alan Breier; David Goldman
Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia.
Lancet 1997;350(9082):930-1.
1997: Christopher J Endres; Bhaskar S Kolachana; Richard C Saunders; T Su; Daniel R Weinberger; Alan Breier; William Eckelman; Richard E Carson
Kinetic modeling of [11C]raclopride: combined PET-microdialysis studies.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 1997;17(9):932-42.
1997: Anil Malhotra; DA Pinals; Caleb M Adler; Igor Elman; A Clifton; DAVID PICKAR; Alan Breier
Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1997;17(3):141-50.
1997: Alan Breier; Anil Malhotra; DA Pinals; NI Weisenfeld; DAVID PICKAR
Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers.
The American journal of psychiatry 1997;154(6):805-11.
1997: Richard E Carson; Alan Breier; Andrea de Bartolomeis; Richard C Saunders; TP Su; B Schmall; Margaret Der; DAVID PICKAR; William Eckelman
Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 1997;17(4):437-47.
1997: Alan Breier; TP Su; R Saunders; Richard E Carson; Bhaskar S Kolachana; Andrea de Bartolomeis; Daniel R Weinberger; NI Weisenfeld; Anil Malhotra; William Eckelman; DAVID PICKAR
Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(6):2569-74.
1997: Robert W Buchanan; M E Strauss; Alan Breier; Brian Kirkpatrick; William T Carpenter
Attentional impairments in deficit and nondeficit forms of schizophrenia.
The American journal of psychiatry 1997;154(3):363-70.
1997: Royce Waltrip II; Robert W Buchanan; William T Carpenter; Brian Kirkpatrick; Ann Summerfelt; Alan Breier; Steven A Rubin; Kathryn M Carbone
Borna disease virus antibodies and the deficit syndrome of schizophrenia.
Schizophrenia research 1997;23(3):253-7.
1997: Igor Elman; Alan Breier
Effects of acute metabolic stress on plasma progesterone and testosterone in male subjects: relationship to pituitary-adrenocortical axis activation.
Life sciences 1997;61(17):1705-12.
1996: DA Pinals; Anil Malhotra; C D Missar; DAVID PICKAR; Alan Breier
Lack of gender differences in neuroleptic response in patients with schizophrenia.
Schizophrenia research 1996;22(3):215-22.
1996: Robert W Buchanan; Brian Kirkpatrick; N Bryant; M Patricia Ball; Alan Breier
Fluoxetine augmentation of clozapine treatment in patients with schizophrenia.
The American journal of psychiatry 1996;153(12):1625-7.
1996: DAVID PICKAR; TP Su; Daniel R Weinberger; Richard Coppola; Anil Malhotra; Michael B Knable; Kan S Lee; Julia G Gorey; J J Bartko; Alan Breier; J Hsiao
Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients.
The American journal of psychiatry 1996;153(12):1571-8.
1996: William T Carpenter; Robert R Conley; Robert W Buchanan; Alan Breier; Carol A Tamminga
Clozapine conflict.
The American journal of psychiatry 1996;153(11):1505-7.
1996: Anil Malhotra; David Goldman; N Ozaki; W Rooney; A Clifton; Robert W Buchanan; Alan Breier; DAVID PICKAR
Clozapine response and the 5HT2C Cys23Ser polymorphism.
Neuroreport 1996;7(13):2100-2.
1996: Anil Malhotra; David Goldman; N Ozaki; Alan Breier; Robert W Buchanan; DAVID PICKAR
Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine.
The American journal of psychiatry 1996;153(8):1092-4.
1996: Jean A Frazier; Jay Giedd; SD Hamburger; K E Albus; D Kaysen; A Catherine Vaituzis; JC Rajapakse; Marge Lenane; K McKenna; L K Jacobsen; Charles T Gordon III; Alan Breier; Judy Rapoport
Brain anatomic magnetic resonance imaging in childhood-onset schizophrenia.
Archives of general psychiatry 1996;53(7):617-24.
1996: Anil Malhotra; David Goldman; Robert W Buchanan; Alan Breier; DAVID PICKAR
5HT 2a receptor T102C polymorphism and schizophrenia.
Lancet 1996;347(9018):1830-1.
1996: J R Bustillo; Robert W Buchanan; D Irish; Alan Breier
Differential effect of clozapine on weight: a controlled study.
The American journal of psychiatry 1996;153(6):817-9.
1996: Anil Malhotra; DA Pinals; H Weingartner; K Sirocco; C D Missar; DAVID PICKAR; Alan Breier
NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1996;14(5):301-7.
1996: Jean A Frazier; Jay Giedd; D Kaysen; K Albus; SD Hamburger; J Alaghband-Rad; Marge Lenane; K McKenna; Alan Breier; Judy Rapoport
Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment.
The American journal of psychiatry 1996;153(4):564-6.
1995: William T Carpenter; Robert R Conley; Robert W Buchanan; Alan Breier; Carol A Tamminga
Patient response and resource management: another view of clozapine treatment of schizophrenia.
The American journal of psychiatry 1995;152(6):827-32.
1995: J L Schreiber; Alan Breier; DAVID PICKAR
Expressed emotion. Trait or state?
The British journal of psychiatry : the journal of mental science 1995;166(5):647-9.
1995: Alan Breier
Serotonin, schizophrenia and antipsychotic drug action.
Schizophrenia research 1995;14(3):187-202.
1995: Royce Waltrip II; Robert W Buchanan; Ann Summerfelt; Alan Breier; William T Carpenter; N L Bryant; Steven A Rubin; Kathryn M Carbone
Borna disease virus and schizophrenia.
Psychiatry research 1995;56(1):33-44.
1994: Robert W Buchanan; C Holstein; Alan Breier
The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.
Biological psychiatry 1994;36(11):717-25.
1994: Robert W Buchanan; M E Strauss; Brian Kirkpatrick; C Holstein; Alan Breier; William T Carpenter
Neuropsychological impairments in deficit vs nondeficit forms of schizophrenia.
Archives of general psychiatry 1994;51(10):804-11.
1994: Alan Breier
Clozapine and noradrenergic function: support for a novel hypothesis for superior efficacy.
The Journal of clinical psychiatry 1994;55 Suppl B():122-5.
1994: Brian Kirkpatrick; Robert W Buchanan; Alan Breier; William T Carpenter
Depressive symptoms and the deficit syndrome of schizophrenia.
The Journal of nervous and mental disease 1994;182(8):452-5.
1994: Robert W Buchanan; P Koeppl; Alan Breier
Stability of neurological signs with clozapine treatment.
Biological psychiatry 1994;36(3):198-200.
1994: A M Elkashef; Robert W Buchanan; FOUAD GELLAD; Robert C Munson; Alan Breier
Basal ganglia pathology in schizophrenia and tardive dyskinesia: an MRI quantitative study.
The American journal of psychiatry 1994;151(5):752-5.
1994: Alan Breier; Robert W Buchanan; Royce Waltrip II; S Listwak; C Holmes; David S Goldstein
The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1994;10(1):1-7.
1994: Alan Breier; Robert W Buchanan; Brian Kirkpatrick; O R Davis; D Irish; Ann Summerfelt; William T Carpenter
Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.
The American journal of psychiatry 1994;151(1):20-6.
1993: Alan Breier; Robert W Buchanan; D Irish; William T Carpenter
Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns.
Hospital & community psychiatry 1993;44(12):1145-9.
1993: Alan Breier; Brian Kirkpatrick; Robert W Buchanan
Clozapine attenuates meta-chlorophenylpiperazine (mCPP)-induced plasma cortisol increases in schizophrenia.
Biological psychiatry 1993;34(7):492-4.
1993: Alan Breier; A M Crane; C Kennedy; L Sokoloff
The effects of pharmacologic doses of 2-deoxy-D-glucose on local cerebral blood flow in the awake, unrestrained rat.
Brain research 1993;618(2):277-82.
1993: J L Schreiber; Alan Breier; DAVID PICKAR
Hospital vs. community.
Hospital & community psychiatry 1993;44(8):795.
1993: Alan Breier; O R Davis; Robert W Buchanan; L A Moricle; Robert C Munson
Effects of metabolic perturbation on plasma homovanillic acid in schizophrenia. Relationship to prefrontal cortex volume.
Archives of general psychiatry 1993;50(7):541-50.
1993: Owen Wolkowitz; H Weingartner; David Rubinow; D Jimerson; M Kling; W Berretini; K Thompson; Alan Breier; A Doran; Victor I Reus
Steroid modulation of human memory: biochemical correlates.
Biological psychiatry 1993;33(10):744-6.
1993: Brian Kirkpatrick; Robert W Buchanan; Alan Breier; William T Carpenter
Case identification and stability of the deficit syndrome of schizophrenia.
Psychiatry research 1993;47(1):47-56.
1993: Robert W Buchanan; Alan Breier; Brian Kirkpatrick; A Elkashef; Robert C Munson; FOUAD GELLAD; William T Carpenter
Structural abnormalities in deficit and nondeficit schizophrenia.
The American journal of psychiatry 1993;150(1):59-65.
1993: Owen Wolkowitz; R Coppola; Alan Breier; A R Doran; David Rubinow; W H Berrettini; M A Kling; DAVID PICKAR
Quantitative electroencephalographic correlates of steroid administration in man.
Neuropsychobiology 1993;27(4):224-30.
1993: D Hommer; H Weingartner; Alan Breier
Dissociation of benzodiazepine-induced amnesia from sedation by flumazenil pretreatment.
Psychopharmacology 1993;112(4):455-60.
1992: Brian Kirkpatrick; William T Carpenter; K Maeda; Robert W Buchanan; Alan Breier; Carol A Tamminga
Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients.
Biological psychiatry 1992;32(11):1049-54.
1992: Alan Breier; Robert W Buchanan; A Elkashef; Robert C Munson; Brian Kirkpatrick; FOUAD GELLAD
Brain morphology and schizophrenia. A magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures.
Archives of general psychiatry 1992;49(12):921-6.
1992: David S Goldstein; Alan Breier; Owen Wolkowitz; DAVID PICKAR; Jacques W M Lenders
Plasma levels of catecholamines and corticotrophin during acute glucopenia induced by 2-deoxy-D-glucose in normal man.
Clinical autonomic research : official journal of the Clinical Autonomic Research Society 1992;2(6):359-66.
1992: Alan Breier; O Davis; Robert W Buchanan; S J Listwak; C Holmes; DAVID PICKAR; David S Goldstein
Effects of alprazolam on pituitary-adrenal and catecholaminergic responses to metabolic stress in humans.
Biological psychiatry 1992;32(10):880-90.
1992: Alan Breier; J L Schreiber; J Dyer; DAVID PICKAR
Course of illness and predictors of outcome in chronic schizophrenia: implications for pathophysiology.
The British journal of psychiatry. Supplement 1992;(18):38-43.
1992: M Albus; T P Zahn; Alan Breier
Anxiogenic properties of yohimbine. II. Influence of experimental set and setting.
European archives of psychiatry and clinical neuroscience 1992;241(6):345-51.
1992: M Albus; T P Zahn; Alan Breier
Anxiogenic properties of yohimbine. I. Behavioral, physiological and biochemical measures.
European archives of psychiatry and clinical neuroscience 1992;241(6):337-44.
1992: Alan Breier; Robert W Buchanan
The effects of metabolic stress on plasma progesterone in healthy volunteers and schizophrenic patients.
Life sciences 1992;51(19):1527-34.
1991: Alan Breier
Panic disorder: clinical features, neurobiology, and pharmacotherapy.
New York state journal of medicine 1991;91(11 Suppl):43S-47S.
1991: William T Carpenter; Robert W Buchanan; Alan Breier; Brian Kirkpatrick; Gunvant K Thaker; Carol A Tamminga
Psychopathology and the question of neurodevelopmental or neurodegenerative disorder.
Schizophrenia research 1991;5(3):192-4.
1991: Alan Breier; J L Schreiber; J Dyer; DAVID PICKAR
National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome.
Archives of general psychiatry 1991;48(3):239-46.
1991: Alan Breier; O R Davis; Robert W Buchanan
Alprazolam attenuates metabolic stress-induced neuroendocrine and behavioral effects in humans.
Psychopharmacology 1991;104(4):479-84.
1991: William T Carpenter; R Kurz; Brian Kirkpatrick; Thomas E Hanlon; Ann Summerfelt; Robert W Buchanan; Royce Waltrip II; Alan Breier
Carbamazepine maintenance treatment in outpatient schizophrenics.
Archives of general psychiatry 1991;48(1):69-72.
1990: Alan Breier; Owen Wolkowitz; A Roy; W Z Potter; DAVID PICKAR
Plasma norepinephrine in chronic schizophrenia.
The American journal of psychiatry 1990;147(11):1467-70.
1990: Owen Wolkowitz; Victor I Reus; H Weingartner; K Thompson; Alan Breier; A Doran; David Rubinow; DAVID PICKAR
Cognitive effects of corticosteroids.
The American journal of psychiatry 1990;147(10):1297-303.
1990: Owen Wolkowitz; David Rubinow; A R Doran; Alan Breier; W H Berrettini; M A Kling; DAVID PICKAR
Prednisone effects on neurochemistry and behavior. Preliminary findings.
Archives of general psychiatry 1990;47(10):963-8.
1990: DAVID PICKAR; Alan Breier; J K Hsiao; A R Doran; Owen Wolkowitz; C N Pato; P E Konicki; William Z Potter
Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia.
Archives of general psychiatry 1990;47(7):641-8.
1990: J L Schreiber; Alan Breier; DAVID PICKAR
Characteristics of patients selected for treatment on a schizophrenia research unit.
Hospital & community psychiatry 1990;41(4):441-3.
1990: Owen Wolkowitz; N M Papadopoulos; R Costello; Alan Breier; A R Doran; DAVID PICKAR; David Rubinow
Prednisone effects on blood-brain barrier permeability and CNS IgG synthesis in healthy humans.
Psychoneuroendocrinology 1990;15(2):155-8.
1990: Alan Breier; S M Paul
The GABAA/benzodiazepine receptor: implications for the molecular basis of anxiety.
Journal of psychiatric research 1990;24 Suppl 2():91-104.
1990: DAVID PICKAR; R E Litman; P E Konicki; Owen Wolkowitz; Alan Breier
Neurochemical and neural mechanisms of positive and negative symptoms in schizophrenia.
Modern problems of pharmacopsychiatry 1990;24():124-51.
1989: Alan Breier
A.E. Bennett award paper. Experimental approaches to human stress research: assessment of neurobiological mechanisms of stress in volunteers and psychiatric patients.
Biological psychiatry 1989;26(5):438-62.
1989: Owen Wolkowitz; A Doran; Alan Breier; A Roy; DAVID PICKAR
Specificity of plasma HVA response to dexamethasone in psychotic depression.
Psychiatry research 1989;29(2):177-86.
1989: Owen Wolkowitz; Alan Breier; A Doran; P Lucas; John R Kelsoe; S M Paul; DAVID PICKAR
Alprazolam augmentation of neuroleptics in schizophrenia.
The American journal of psychiatry 1989;146(8):1087-8.
1989: A R Doran; David Rubinow; Owen Wolkowitz; A Roy; Alan Breier; DAVID PICKAR
Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: correlations with CSF HVA.
Biological psychiatry 1989;25(4):431-9.
1988: Alan Breier; John R Kelsoe; P D Kirwin; S A Beller; Owen Wolkowitz; DAVID PICKAR
Early parental loss and development of adult psychopathology.
Archives of general psychiatry 1988;45(11):987-93.
1988: Alan Breier; Owen Wolkowitz; A R Doran; S Bellar; DAVID PICKAR
Neurobiological effects of lumbar puncture stress in psychiatric patients and healthy volunteers.
Psychiatry research 1988;25(2):187-94.
1988: Owen Wolkowitz; Alan Breier; A Doran; John R Kelsoe; P Lucas; S M Paul; DAVID PICKAR
Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results.
Archives of general psychiatry 1988;45(7):664-71.
1988: Alan Breier
Stress isn't always bad.
Hospital & community psychiatry 1988;39(6):591.
1988: Owen Wolkowitz; Alan Breier; A Doran; David Rubinow; W Berrettini; R Coppola; P Gold; DAVID PICKAR
Prednisone-induced behavioral and biological changes in medically healthy volunteers.
Psychopharmacology bulletin 1988;24(3):492-4.
1988: Alan Breier
Small sample studies: unique contributions for large sample outcome studies.
Schizophrenia bulletin 1988;14(4):589-93.
1988: DAVID PICKAR; Alan Breier; John R Kelsoe
Plasma homovanillic acid as an index of central dopaminergic activity: studies in schizophrenic patients.
Annals of the New York Academy of Sciences 1988;537():339-46.
1988: Alan Breier; Owen Wolkowitz; M Rapaport; S M Paul; DAVID PICKAR
Metabolic stress effects in normal volunteers and schizophrenic patients.
Psychopharmacology bulletin 1988;24(3):431-3.
1987: Alan Breier; Owen Wolkowitz; A R Doran; A Roy; J Boronow; Daniel W Hommer; DAVID PICKAR
Neuroleptic responsivity of negative and positive symptoms in schizophrenia.
The American journal of psychiatry 1987;144(12):1549-55.
1987: A R Doran; J Boronow; Daniel R Weinberger; Owen Wolkowitz; Alan Breier; DAVID PICKAR
Structural brain pathology in schizophrenia revisited. Prefrontal cortex pathology is inversely correlated with cerebrospinal fluid levels of homovanillic acid.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1987;1(1):25-32.
1987: Alan Breier; P K Arora; Owen Wolkowitz; DAVID PICKAR; S M Paul
Metabolic stress produces rapid immunosuppression in humans.
Archives of general psychiatry 1987;44(12):1108-9.
1987: Alan Breier; M Albus; DAVID PICKAR; T P Zahn; Owen Wolkowitz; S M Paul
Controllable and uncontrollable stress in humans: alterations in mood and neuroendocrine and psychophysiological function.
The American journal of psychiatry 1987;144(11):1419-25.
1987: Owen Wolkowitz; David Rubinow; Alan Breier; A R Doran; C Davis; DAVID PICKAR
Prednisone decreases CSF somatostatin in healthy humans: implications for neuropsychiatric illness.
Life sciences 1987;41(16):1929-33.
1987: Owen Wolkowitz; A R Doran; Alan Breier; A Roy; D C Jimerson; M E Sutton; R N Golden; S M Paul; DAVID PICKAR
The effects of dexamethasone on plasma homovanillic acid and 3-methoxy-4-hydroxyphenylglycol. Evidence for abnormal corticosteroid-catecholamine interactions in major depression.
Archives of general psychiatry 1987;44(9):782-9.
1987: C M Harding; G W Brooks; T Ashikaga; J S Strauss; Alan Breier
The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia.
The American journal of psychiatry 1987;144(6):727-35.
1987: C M Harding; G W Brooks; T Ashikaga; J S Strauss; Alan Breier
The Vermont longitudinal study of persons with severe mental illness, I: Methodology, study sample, and overall status 32 years later.
The American journal of psychiatry 1987;144(6):718-26.
1987: DAVID PICKAR; Owen Wolkowitz; A R Doran; R Labarca; A Roy; Alan Breier; P K Narang
Clinical and biochemical effects of verapamil administration to schizophrenic patients.
Archives of general psychiatry 1987;44(2):113-8.
1987: DAVID PICKAR; Owen Wolkowitz; R Labarca; A R Doran; Alan Breier; S M Paul
Biochemical alterations produced by neuroleptics in man: studies of plasma homovanillic acid in schizophrenic patients.
Psychopharmacology series 1987;3():248-54.
1986: Alan Breier; D S Charney; G R Heninger
Agoraphobia with panic attacks. Development, diagnostic stability, and course of illness.
Archives of general psychiatry 1986;43(11):1029-36.
1986: Alan Breier; D S Charney; G R Heninger
Intravenous diazepam fails to change growth hormone and cortisol secretion in humans.
Psychiatry research 1986;18(4):293-9.
1986: DAVID PICKAR; R Labarca; A R Doran; Owen Wolkowitz; A Roy; Alan Breier; M Linnoila; S M Paul
Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment.
Archives of general psychiatry 1986;43(7):669-76.
1986: Owen Wolkowitz; A R Doran; Alan Breier; M R Cohen; DAVID PICKAR
Endogenous opioid regulation of hypothalamo-pituitary-adrenal axis activity in schizophrenia.
Biological psychiatry 1986;21(4):366-73.
1986: A R Doran; Alan Breier; A Roy
Differential diagnosis and diagnostic systems in schizophrenia.
The Psychiatric clinics of North America 1986;9(1):17-33.
1986: D S Charney; G R Heninger; L H Price; Alan Breier
Major depression and panic disorder: diagnostic and neurobiological relationships.
Psychopharmacology bulletin 1986;22(2):503-11.
1986: D S Charney; Alan Breier; P I Jatlow; G R Heninger
Behavioral, biochemical, and blood pressure responses to alprazolam in healthy subjects: interactions with yohimbine.
Psychopharmacology 1986;88(2):133-40.
1986: Owen Wolkowitz; DAVID PICKAR; A R Doran; Alan Breier; J Tarell; S M Paul
Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia.
The American journal of psychiatry 1986;143(1):85-7.
1986: DAVID PICKAR; A Roy; Alan Breier; A Doran; Owen Wolkowitz; J Colison; Hans Agren
Suicide and aggression in schizophrenia. Neurobiologic correlates.
Annals of the New York Academy of Sciences 1986;487():189-96.
1985: Alan Breier; D S Charney; G R Heninger
The diagnostic validity of anxiety disorders and their relationship to depressive illness.
The American journal of psychiatry 1985;142(7):787-97.
1985: A R Doran; P K Narang; C Y Meigs; Owen Wolkowitz; A Roy; Alan Breier; DAVID PICKAR
Verapamil concentrations in cerebrospinal fluid after oral administration.
The New England journal of medicine 1985;312(19):1261-2.
1984: Alan Breier; D S Charney; G R Heninger
Major depression in patients with agoraphobia and panic disorder.
Archives of general psychiatry 1984;41(12):1129-35.
1984: Alan Breier; D S Charney; J C Nelson
Seizures induced by abrupt discontinuation of alprazolam.
The American journal of psychiatry 1984;141(12):1606-7.
1984: D S Charney; G R Heninger; Alan Breier
Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder.
Archives of general psychiatry 1984;41(8):751-63.
1984: Alan Breier; J S Strauss
The role of social relationships in the recovery from psychotic disorders.
The American journal of psychiatry 1984;141(8):949-55.
1984: Alan Breier; E M Ginsberg; D S Charney
Seminal emission induced by tricyclic antidepressant.
The American journal of psychiatry 1984;141(4):610-11.
1984: Alan Breier; B M Astrachan
Characterization of schizophrenic patients who commit suicide.
The American journal of psychiatry 1984;141(2):206-9.
1983: Alan Breier; J S Strauss
Self-control in psychotic disorders.
Archives of general psychiatry 1983;40(10):1141-5.
1981: Alan Breier; Robert Hitzemann; J Hirschowitz; D L Garver
Kinetic analysis of platelet monoamine oxidase in chronic schizophrenia.
Life sciences 1981;28(17):1947-51.